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Brief Clinical Reportsand RA pressure differences caused by the inadvertently
misconnected IVC. This case stresses the role of intraopera-
tive transesophageal echocardiographic analysis even in
simple cases, such as an ASD.References
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O. Howard Frazier, MD,d Oxford, Birmingham, and London, United Kingdom; and Houston, TexSeverely symptomatic heart failure is increasingly common as
the population ages. Both prognosis and quality of life are
poor. These patients have limited options. Few are eligible
for cardiac transplantation because of age or the common
transplant comorbidities of pulmonary hypertension and
renal impairment. In New York Heart Association (NYHA)
class IV patients, ventricular resynchronization therapy pro-
vides only marginal benefit that is insufficient to improve
quality of life.1 Lifetime circulatory support has a firm evi-
dence base in the REMATCH trial.2 Because of the complica-
tion rates in first-generation left ventricular assist devices
(LVADs), the compelling argument for an off-the-shelf solu-
tion for advanced heart failure has been slow to progress.
In 2000, we reported the first implantation of a new mini-
aturized rotary blood pump with a novel power-delivery sys-
tem designed for permanent use.3 At the time, there was
skepticism about the ability of a nonpulsatile LVAD to sus-
tain end-organ function on a long-term basis. In fact, the pa-
tient became the world’s longest circulatory support
survivor. We now describe the autopsy findings to conclude
this experience.CLINICAL SUMMARY
The patient was a 60-year-old man with a 7-year history of
symptomatic idiopathic dilated cardiomyopathy leading to
breathlessness at rest, pitting edema to the thighs, ulcerated
legs, and ascites, despite maximum medical therapy. Left
ventricular ejection fraction was less than 10%, with a car-
diac index of 1.81 L $ min1 $ m2. Maximal oxygen con-
sumption was 5.7 mL $ kg1 $ min1 during exercise, and
pulmonary vascular resistance was 7Wood units. With a sin-
gle functioning kidney and a creatinine clearance of 38 mL/
min, he was not accepted for the transplant wait listing.
The Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New
York, NY) was implanted directly into the apex of the left
ventricle with a Dacron graft to the descending thoracic aorta
(Figure 1, A). The power-delivery system used a titanium
pedestal screwed into the skull, providing a plug into which
the external power line, battery, and controller were attached
(Figure 1, B).4 Postoperative management included anticoa-
gulation with warfarin to maintain an international normal-
ized ratio of between 2.5 and 3.0, together with continuous
pharmacologic afterload reduction. Mean blood pressure
was between 80 and 90 mm Hg, usually with a pulse pres-
sure of 10 to 15 mm Hg. At a pump rotor speed of 10,000
rpm, resting cardiac output was between 4.5 and 5.5 L/
min. Over 3 months, the patient returned to NYHA class I.
He led a very active and productive life for 7.5 years. After
the perioperative period, less than 5% of the follow-up dura-
tion was spent in the hospital. There were no pump
malfunctions or thromboembolic complications. External ca-
bles and batteries were exchanged on numerous occasions
through wear and tear. The skull pedestal remained infection
free. Staphylococcal septicemia followed nasal cauterization
for epistaxis but was successfully treated with a 3-monthrdiovascular Surgery c Volume 139, Number 3 e45
FIGURE 1. A, The Jarvik 2000 axial flow pump and vascular graft. B, The titanium skull pedestal designed to transmit electrical power across the skin while
minimizing the risk of infection. Resistance to infection occurs through rigid fixation and highly vascular scalp skin without a subcutaneous fat layer. This was
the first clinical application of the technique. C, Plain chest, neck, and skull radiographs showing the left ventricular assist device implanted within the left
ventricle and the power cable passing through the pleural cavity and neck to the skull-fixed pedestal.
Brief Clinical Reportscourse of antibiotics.Over time, the performance of theLVAD
remainedunchanged, but heart and renal functiondeteriorated.
In the last 2 years of life, hewas inNYHAclass II and troubled
by rheumatoid arthritis and benign prostatic hypertrophy. The
latter was managed by means of transurethral resection. He
died at 68 years of age after profuse epistaxis and then acute
renal failure. Hewas optimally anticoagulatedwith an interna-
tional normalized ratio of 2.5 at the time. The overall cost per
annum for this patient, including the LVAD, was $40,000.
A detailed autopsy was performed, with removal of the in-
tracardiac blood pump and power system intact. The left
ventricle was hugely dilated (heart weight, 794 g), but the
coronary arteries were normal. Histology confirmed chronic
idiopathic dilated cardiomyopathy, and the pulmonary ar-
teries showed intimal thickening consistent with pulmonary
hypertension. There was a thin crescent of densely adherent
thrombus between the device and the septum of the left ven-
tricle. No thrombus was found within the device or vascular
graft. Careful examination of the brain, liver, kidneys, and
gut provided no evidence for silent embolism, infarction,
or hemorrhage. The kidneys showed globally sclerosed glo-
meruli and tubular atrophy, accounting for the chronic renal
impairment. We were particularly interested in the long-term
effects of attenuated pulse pressure, but apart from decreased
numbers of smooth muscle cells in the aortic medial layer,
no other changes in organ histology were detectable.e46 The Journal of Thoracic and Cardiovascular SurgThe axial flow pump itself showed only minimal wear in
the ceramic bearings and continues to work normally during
ongoing durability testing on the bench. The implanted
power-delivery system was free from infection (Figure 1,
C). Consequently, there was no indication that any part of
the mechanical system would fail in the foreseeable future.
DISCUSSION
This anecdotal experience illustrates the true potential for
destination therapy and confirms that physiologic levels of
pulse pressure are not a fundamental requirement in the hu-
man circulation. Modest increases in blood flow (range, 3–4
L/min) can relieve symptoms and reverse both the humeral
and cytokine changes of heart failure. Although high-vol-
ume pulsatile LVAD flow might be preferable for moribund
bridge-to-transplantation patients with multiple organ fail-
ure, the target population for destination therapy has chronic
ambulatory heart failure and can be rendered asymptomatic
with a continuous-flow device.
In our patient the LVAD sustained the systemic circulation
and palliated symptoms for more than 10% of his overall life-
span. The cost did not exceed the benchmark $50,000 per
added life-year for patients undergoing renal dialysis. A second
patient receiving a Jarvik 2000 is approaching 7 years of sur-
vival (F. Beyersdorf, personal communication), whereas the
Berlin INCOR (BerlinHeart, Berlin, Germany) andHeartMateery c March 2010
Brief Clinical ReportsII (Thoratec, Pleasanton, Calif) axial flow pumps have sus-
tained patients for 4 years. Given the reservations about sur-
vival advantage and economic viability of cardiac
transplantation in United Network for Organ Sharing status II
patients, properly structured clinical trials to compare LVADs
with transplantation or continuedmedical therapy are indicated
and probably overdue.5 Indeed, for thosewhowish to avoid the
side effects of immunosuppression, a rotary blood pumpmight
provide a realistic alternative to a donor heart.
In the meantime, rotary blood pumps can offer symptom-
atic relief for many patients with heart failure who will never
reach a transplant waiting list.From Cardiopulmonary Transplantation, University of Pittsburgh Medical Center,
Pittsburgh, Pa.
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Joseph Pilewski, MD, and Yoshiya Toyoda, MD, Pittsburgh, PaAdvanced recipient age continues to be used as an exclusion
criterion for lung transplantation.1 However, given the
changing age demographics in most developed countries,
redefinition of the appropriate recipient age limit for lung
transplantation is needed because it has become an estab-
lished therapeutic option with acceptable mortality for end-
stage lung diseases. Given those conditions, we recently have
expanded our criteria for both recipients and donors in lung
transplantation.2 We present the case of an 81-year-old man
with idiopathic pulmonary fibrosis (IPF) who is the oldest
known successful lung transplant recipient reported.CLINICAL SUMMARY
An 81-year-old man who had been an active businessman
and enjoyed golf after retirementwas given a diagnosis of IPF
in 2005 and treated with oral steroids and azathioprine. He
became oxygen dependent and severely limited in activities
of daily living (from Fletcher Hugh–Jones criteria 4 to 5). Af-
ter failing all other therapeutic initiatives, he was referred to
one major medical center in the United States for lung trans-
plantation evaluation. However, because of his advancedage, he was declined and referred to our center to re-evaluate
his lung transplantation candidacy. Although the patient had
a past history of prostate cancer in 1992, there was no evi-
dence of recurrence during the 5 years before our re-evalua-
tion, and he was deemed a suitable candidate based on our
multidisciplinary transplant selection committee criteria. At
the time of listing, he had severely restrictive pulmonary
function, with a forced vital capacity of 1.59 L (41% of pre-
dicted value), a forced expiratory volume in 1 second of 1.35
L (56% of predicted value), and a diffusion capacity for car-
bon monoxide of 3.88 L/min/kpa (23% of predicted value).
Furthermore, blood gas on room air showed a PO2 of 48 mm
Hg and a PCO2 of 36 mmHg. The 6-minute walk results were
770 feet on 6 L of oxygen through a nasal cannula with desa-
turation to 85%. Cardiac catheterization showed a systolic
pulmonary artery pressure of 43 mm Hg, a transpulmonary
gradient of 15 mm Hg, and mild coronary artery disease.
A chest radiograph on admission is shown in Figure 1, A.
In April 2007, a 51-year-old man with no smoking history
became available as a donor. The donor was 66 inches in
height, whereas the recipient was 68 inches. We performed
a left single-lung transplantation without cardiopulmonary
bypass, during which the allograft ischemic time was 245
minutes. Immunosuppressive therapy consisted of intrave-
nous alemtuzumab (Campath-1H; Genzyme Corporation,
Cambridge, Mass) as induction therapy, with oral tacrolimus,
mycophenolate mofetil, and prednisone administered postop-
eratively. Recovery from the procedure was uneventful. He
was extubated on postoperative day 1 and was discharged
from the hospital 21 days after transplantation without supple-
mental oxygen. At present, 1 year after transplantation, therdiovascular Surgery c Volume 139, Number 3 e47
